31.12.2014 - NeuroDerm shares rose after the publication of a new drug research
The stock price of NeuroDerm shows a significant increase against the background of statements by representatives of the company on promising results of a trial of treatment of Parkinson's disease. Certification and production of the drug can bring the company significant profits. These drugs may be more effective than surgery and more accessible to patients. Let us recall that the company's shares went public in November. We recommend buying the stocks.